Obsidian Therapeutics (NASDAQ:OBX – Get Free Report) was the recipient of a large increase in short interest in September. As of September 30th, there was short interest totaling 884,528 shares, an increase of 249.5% from the September 15th total of 253,084 shares. Based on an average trading volume of 1,019,181 shares, the short-interest ratio is presently 0.9 days. Approximately 1.4% of the shares of the stock are short sold.
Obsidian Therapeutics Stock Performance
NASDAQ:OBX traded up $0.76 during midday trading on Friday, hitting $13.00. The company had a trading volume of 532,198 shares, compared to its average volume of 727,398. Obsidian Therapeutics has a 52-week low of $12.07 and a 52-week high of $49.97. The stock has a fifty day simple moving average of $18.25.
Wall Street Analyst Weigh In
Several research analysts have recently commented on the company. Zacks Research raised Obsidian Therapeutics to a “hold” rating in a report on Thursday, August 6th. William Blair raised shares of Obsidian Therapeutics to a “strong-buy” rating in a research note on Wednesday, September 23rd. Weiss Ratings started coverage on shares of Obsidian Therapeutics in a research note on Wednesday, September 2nd. They issued a “sell (d-)” rating on the stock. Piper Sandler assumed coverage on shares of Obsidian Therapeutics in a research report on Wednesday, August 5th. They set an “overweight” rating and a $42.00 target price for the company. Finally, Lifesci Capital initiated coverage on shares of Obsidian Therapeutics in a research note on Tuesday, August 18th. They issued an “outperform” rating and a $43.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $39.00.
Obsidian Therapeutics Company Profile
Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for serious diseases. Its research centers on technologies designed to control the activity, timing and location of therapeutic proteins within engineered cells.
The company’s CytoDRiVE platform is intended to enable small-molecule regulation of protein expression, which may help improve the safety and effectiveness of cell therapies. Obsidian has applied this technology to immune-cell therapies, including programs designed to support the treatment of solid tumors, as well as to other therapeutic protein and gene-modulation applications.
Obsidian Therapeutics is based in the United States and has operated as a privately held biotechnology company, according to available company information.
Further Reading
- Five stocks we like better than Obsidian Therapeutics
- 3 Stocks Chopped in Half: Why These Drops May Be Structural, Not a Dip
- Home Depot and Lowe’s Hit 52-Week Lows—But Analysts Aren’t Giving Up
- Utilities Are Bouncing Back—These 2 Giants Could Signal the Next Big Sector Rally
- Q3 Earnings Could Blow Past Consensus—Be Ready for What Comes Next
Receive News & Ratings for Obsidian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obsidian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
